CAJ | 학술논문

目的探讨新辅助放化疗对直肠癌细胞凋亡、增殖以及侵袭能力的影响,为新辅助放化疗在直肠癌中的应用提供依据.方法选取新辅助放化疗的中低位直肠癌患者(研究组)及未行新辅助放化疗的中低位直肠癌患者(对照组)术后石蜡包埋组织进行对照研究.检测与直肠癌生物学特性相关指标(如癌胚抗原、增殖细胞核抗原及血管内皮生长因子受体2)在两组之间的表达差异.结果研究组和对照组CEA在直肠癌组织中的阳性表达分别为:83.33％( 50/60)、98.33％( 59/60),两者比较差异有显著性(P＜0.05)；研究组和对照组PCNA在直肠癌组织中的阳性表达分别为:83.33％( 50/60)、96.67％( 58/60),两者比较差异有显著性(P＜0.05)；研究组和对照组VEGFR2在直肠癌组织中的阳性表达分别为:46.67％( 28/60)、81.67％( 49/60),两者比较差异有极显著性(P＜0.01).结论新辅助放化疗可使直肠癌肿瘤细胞的侵袭能力降低,可能有利于直肠癌患者的预后.
목적 탐토신보조방화료대직장암세포조망、증식이급침습능력적영향,위신보조방화료재직장암중적응용제공의거.방법 선취신보조방화료적중저위직장암환자(연구조)급미행신보조방화료적중저위직장암환자(대조조)술후석사포매조직진행대조연구.검측여직장암생물학특성상관지표(여암배항원、증식세포핵항원급혈관내피생장인자수체2)재량조지간적표체차이.결과 연구조화대조조CEA재직장암조직중적양성표체분별위:83.33％( 50/60)、98.33％( 59/60),량자비교차이유현저성(P＜0.05)；연구조화대조조PCNA재직장암조직중적양성표체분별위:83.33％( 50/60)、96.67％( 58/60),량자비교차이유현저성(P＜0.05)；연구조화대조조VEGFR2재직장암조직중적양성표체분별위:46.67％( 28/60)、81.67％( 49/60),량자비교차이유겁현저성(P＜0.01).결론 신보조방화료가사직장암종류세포적침습능력강저,가능유리우직장암환자적예후.
Objective To provide reliable support for the application of neoadjuvant therapy for advanced rectal cancer by exploring the impacts of the therapy on apoptosis,proliferation,and invasive ability of the cancer cells.Methods Postoperative paraffin sections from patients receiving neoadjuvant therapy ( study group ) and from those receiving no neoadjuvant therapy ( control group ) were examined.The expression differences of oncobiology-associated markers including carcino-embryonic antigen ( CEA ),proliferating cell nuclear antigen ( PCNA ),and vascular endothelial growth factor receptor2 ( VEGFR2 ) were compared between the two groups.Results The positive rates of CEA,PCNA,and VEGFR2 were significantly lower in the study group than in the control group ( 98.33％ vs.83.33％,X2=9.08,P=0.028 for CEA ; 96.67％vs.83.33％,X2=9.51,P=0.023forPCNA; and81.67％vs.46.67％,X 2=16.32,P=0.001 for VEGFR2 ).Conclusions Neoadjuvant therapy can reduce the invasive ability of rectal cancer cells,which may be beneficial to the prognosis of patients with rectal cancer.